anti plau  (Boster Bio)

Journal: Investigative Ophthalmology & Visual Science

Article Title: Integrated Transcriptomics and Experimental Validation Reveal That Ellagic Acid Alleviates Fuchs Endothelial Corneal Dystrophy via PLAU/NF-κB Signaling

doi: 10.1167/iovs.67.1.31

Figure Lengend Snippet: In vitro experiments confirming ellagic acid (EA) target on PLAU to regulate NF-κB signaling pathway in corneal endothelial cells. ( A – C ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in H 2 O 2 -treated B4G12 cells, with or without EA treatment. The relative protein expression levels are shown for B PLAU and C the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( D – F ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 in UVA-irradiated B4G12 cells, with or without EA treatment. Relative protein expression levels are shown for E PLAU and F the ratio of phospho-NF-κB p65 to total NF-κB p65 ( n = 3). ( G – I ) Western blot analysis of PLAU, NF-κB p65, and phospho-NF-κB p65 following siPLAU treatment in H 2 O 2 -treated B4G12 cells, with or without EA. Relative protein expression levels are presented for G PLAU and I the ratio of phospho-NF-κB p65 to NF-κB p65 ( n = 3 for PLAU, and n = 4 for phospho-NF-κB p65 to NF-κB p65). ( J ) Schematic diagram illustrating the proposed anti-inflammatory and anti-oxidant mechanisms of EA in FECD, highlighting its role in modulating the NF-κB pathway. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01 by 1-way ANOVA with Tukey’s post hoc test.

Article Snippet: Primary antibodies against PLAU (Proteintech, China; #17968-1-AP), NF-κB p65 (Abcam, UK; #ab32536), phospho-NF-κB p65 (S536; Abcam, UK; #ab76302), GAPDH (ABclonal, China; #AC002), and β-Actin (ABclonal, China; #AC004) were applied overnight at 4°C.

Techniques: In Vitro, Western Blot, Expressing, Irradiation

Journal: Cancer Cell International

Article Title: Stromal PLAU mediates tumor progression and informs a novel therapeutic target in triple-negative breast cancer

doi: 10.1186/s12935-025-03867-y

Figure Lengend Snippet: PLAU knockdown in CAFs suppressed tumor growth of TNBC in vivo. ( A ) Gross appearance of tumor xenografts in control and sh-PLAU groups. n = 5. ( B ) Tumor growth curve of two groups. (*, p <0.05). ( C ) IHC staining of PLAU, Ki-67,α-SMA and MMP2 in the tumor tissues. ( D ) Scatter plot showing correlation between PLAU with the expression of ACTA2, MMP2, ITGAV and CTSB in TCGA-TNBC dataset by Spearman’s correlation tests. ( E ) The mechanism diagram of the study.

Article Snippet: The primary antibodies were listed as follows: PLAU (Proteintech, 17968-1-AP), Ki-67 (Abcam, ab15580), α-SMA(Servicrbio, GB111364 ), MMP2(Servicrbio, GB11130).

Techniques: Knockdown, In Vivo, Control, Immunohistochemistry, Expressing

Journal: Cancer genetics

Article Title: PLAU serves as a prognostic biomarker correlated with perineural invasion in HNSCC.

doi: 10.1016/j.cancergen.2025.04.008

Figure Lengend Snippet: Fig. 3. Overexpression of PLAU is related to PNI in patients with HNSCC. a Typical picture of Ki67, PLAU, NGF, PGP9.5 in tissue microarrays staining of 68 patients with laryngeal and hypopharyngeal carcinomas. b-e Statistical analysis of Ki67, PLAU, NGF, PGP9.5 expression in PNI positive and negative patients. f-h Spearman correlation between PLAU, NGF and PGP9.5. ***P < 0.001, ****P < 0.0001.

Article Snippet: After a series of tissue dewaxing, hydration and antigen repair, a drop of primary antibody was added (the concentration of antibody was adjusted slightly according to the actual situation, PGP9.5 Item No. Abclonal A19101 1:100, PLAU Item No. Proteintech 17968-1-AP 1:100, NGF Item No. Abcam ab52918 1:200, KI67 Item No. Proteintech 27309- 1-AP 1:1000).

Techniques: Over Expression, Staining, Expressing

Journal: Cancer genetics

Article Title: PLAU serves as a prognostic biomarker correlated with perineural invasion in HNSCC.

doi: 10.1016/j.cancergen.2025.04.008

Figure Lengend Snippet: Fig. 4. PLAU is able to promote the capacity of proliferation and migration in HNSCC cells. a, b WB validation of the knockdown and overexpression efficiency of PLAU in FaDu and Tu686 cells. c, d The CCK8 assay measured the effect of PLAU inhibition or overexpression on cell proliferation. e-g Transwell assay was used to assess the effect of inhibiting or overexpressing PLAU on cell migration ability. h-j Addition of some inhibitors of PLAU and NGF respectively to detect changes in the ability of cell proliferation and migration by CCK8 and Transwell assays. **P < 0.01, ***P < 0.001.

Article Snippet: After a series of tissue dewaxing, hydration and antigen repair, a drop of primary antibody was added (the concentration of antibody was adjusted slightly according to the actual situation, PGP9.5 Item No. Abclonal A19101 1:100, PLAU Item No. Proteintech 17968-1-AP 1:100, NGF Item No. Abcam ab52918 1:200, KI67 Item No. Proteintech 27309- 1-AP 1:1000).

Techniques: Migration, Biomarker Discovery, Knockdown, Over Expression, CCK-8 Assay, Inhibition, Transwell Assay

Journal: Cancer genetics

Article Title: PLAU serves as a prognostic biomarker correlated with perineural invasion in HNSCC.

doi: 10.1016/j.cancergen.2025.04.008

Figure Lengend Snippet: Fig. 6. PLAU promotes tumor growth in vivo. a Schematic of mice subcutaneous tumorigenesis model. b-d FaDu cells were transplanted subcutaneously into nude mice and divided into NC, UKI-1 and Ro 08-2750 groups (UKI-1 and Ro 08-2750 inhibit PLAU and NGF, respectively). The corresponding drugs were injected intraperitoneally on days 1, 4, 7, 10, 13, 16 and 19, the tumors were removed on day 22 and the weight and volume of subcutaneous tumors were measured. e-g The same method was adopted for Tu686 cells as in b-d. h-l Representative immunohistochemical staining of Ki67, PLAU, NGF, PGP9.5 and statistical analysis of respective staining intensity scores. m Schematic overview of interaction between nerve cells and HNSCC cells. Briefly, HNSCC cells have the capability to secrete PLAU and NGF to nerve cells, facilitating the development of PNI and subsequently enhancing tumor advancement. On this basis, the inhibition of PLAU and NGF through UKI-1 and Ro 08-2750 has proven to be efficacious in impeding tumor progression. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: After a series of tissue dewaxing, hydration and antigen repair, a drop of primary antibody was added (the concentration of antibody was adjusted slightly according to the actual situation, PGP9.5 Item No. Abclonal A19101 1:100, PLAU Item No. Proteintech 17968-1-AP 1:100, NGF Item No. Abcam ab52918 1:200, KI67 Item No. Proteintech 27309- 1-AP 1:1000).

Techniques: In Vivo, Injection, Immunohistochemical staining, Staining, Inhibition